Biovie Inc. (BIVI) Stock Price & Analysis
Biovie Inc. (BIVI) rose 0.00% to USD 1.67 as of June 10, 2026 at 09:52 UTC, according to Nexqual real-time market data.
BIVI last closed at USD 1.67; the session ranged USD 1.61–1.76 on volume of 69,234 shares. Market capitalization is $12.59M, with a 52-week range of USD 1.06–12.1 (NCM). Source: Nexqual, June 10, 2026 at 09:52 UTC.
Key Statistics (as of June 10, 2026 at 09:52 UTC)
| Price | USD 1.67 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 1.67 |
| Open | USD 1.66 |
| Day Range | USD 1.61 – 1.76 |
| 52-Week Range | USD 1.06 – 12.1 |
| Volume | 69,234 shares |
| Market Cap | $12.59M |
| Exchange | NCM |
Technical Analysis (BIVI)
Nexqual's technical model rates BIVI "STRONG BUY" based on 5 bullish and 0 bearish signals across 123 daily candles, as of June 10, 2026 at 09:52 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 57.7 (neutral) |
| vs SMA50 | Above (USD 1.49) |
| MACD | 0.05 (positive) |
Analyst Ratings (BIVI)
Wall Street analysts rate BIVI "Strong Buy" based on 1 analysts, with a mean price target of USD 5 (range USD 5–5), per Nexqual as of June 10, 2026 at 09:52 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 1 |
| Mean Target | USD 5 |
| High Target | USD 5 |
| Low Target | USD 5 |
| Buy / Hold / Sell | 1 / 0 / 0 |
Earnings (BIVI)
| Next Earnings Date | 2026-05-11 |
|---|
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2025-09-30 | USD -0.98 vs est -0.79 ▼ miss |
| 2025-06-30 | USD -11.05 vs est -3.6 ▼ miss |
| 2025-03-31 | USD -1.5 vs est -3.2 ▲ beat |
Source: Nexqual, June 10, 2026 at 09:52 UTC.
Financials & Fundamentals (BIVI)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -106.43% |
| Debt / Equity | 1.9 |
| Current Ratio | 9.97 |
| Total Cash | $13.10M |
| Total Debt | $295,717 |
| Free Cash Flow | $-14.26M |
Source: Nexqual, June 10, 2026 at 09:52 UTC.
Financial Health Score (BIVI)
Nexqual rates Biovie Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 09:52 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $13M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$21M |
| Efficiency | Critical — ROE -106%, ROA -61.0% |
Ownership (BIVI)
| Insider Ownership | +0.36% |
|---|---|
| Institutional Ownership | +13.94% |
| Shares Outstanding | 7.54M |
| Float | 7.50M |
| Short % of Float | +2.51% |
Source: Nexqual, June 10, 2026 at 09:52 UTC.
Leadership (BIVI)
Biovie Inc. is led by Cuong Viet Do (age 59), President, CEO & Director, per Nexqual as of June 10, 2026 at 09:52 UTC.
| President, CEO & Director | Cuong Viet Do (age 59) |
|---|---|
| CFO, Treasurer & Corporate Secretary | Joanne Wendy Kim (age 69) |
| Senior Vice President of Operations | Clarence N. Ahlem (age 69) |
| Senior Vice President of Liver Disease Program | Penelope Markham (age 59) |
| Senior Vice President of Manufacturing & Development | Denise Smith |
Major Backers & Investors (BIVI)
Notable institutional backers of Biovie Inc. include Diametric Capital, Lp, Prelude Capital Management LLC, Morgan Stanley, according to Nexqual as of June 10, 2026 at 09:52 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Diametric Capital, Lp | 4.91% |
| Prelude Capital Management LLC | 1.22% |
| Morgan Stanley | 1% |
| Philadelphia Trust Company | 0.99% |
| Fidelity | 0.91% |
| Renaissance Technologies | 0.9% |
| Citadel | 0.6% |
| HRT Financial LP | 0.31% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 2.72% |
| Geode Capital | 1.12% |
Source: Nexqual, June 10, 2026 at 09:52 UTC.
From Biovie Inc.'s Latest SEC 10-K Filing (filed 2025-08-15)
Key Strengths & Strategy (as disclosed to the SEC)
- BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States.
- The company develops BIV201, that is in phase 2 for the treatment of ascites due to chronic liver cirrhosis.
- It also develops NE3107 that is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease; and in Phase 2 clinical trial to treat Parkinson's disease, as well as for the long COVID program.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ENSC | Ensysce Biosciences, Inc. | USD 0.25 | ▲ 0% |
| BCDA | BioCardia, Inc. | USD 0.86 | ▼ 16.5% |
| GRI | GRI Bio, Inc. | USD 2.2 | ▲ 10% |
| DRUG | Bright Minds Biosciences Inc. | USD 67.8 | ▼ 1.74% |
| TVGN | Tevogen Bio Holdings Inc. | USD 10.75 | ▲ 2.67% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 09:52 UTC. This page is informational and not investment advice.